Literature DB >> 22014094

Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.

Kenichi Akaji1, Hiroyuki Konno, Hironori Mitsui, Kenta Teruya, Yasuhiro Shimamoto, Yasunao Hattori, Takeshi Ozaki, Masami Kusunoki, Akira Sanjoh.   

Abstract

The design and evaluation of low molecular weight peptide-based severe acute respiratory syndrome (SARS) chymotrypsin-like protease (3CL) protease inhibitors are described. A substrate-based peptide aldehyde was selected as a starting compound, and optimum side-chain structures were determined, based on a comparison of inhibitory activities with Michael type inhibitors. For the efficient screening of peptide aldehydes containing a specific C-terminal residue, a new approach employing thioacetal to aldehyde conversion mediated by N-bromosuccinimide was devised. Structural optimization was carried out based on X-ray crystallographic analyses of the R188I SARS 3CL protease in a complex with each inhibitor to provide a tetrapeptide aldehyde with an IC(50) value of 98 nM. The resulting compound carried no substrate sequence, except for a P(3) site directed toward the outside of the protease. X-ray crystallography provided insights into the protein-ligand interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014094     DOI: 10.1021/jm200870n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  45 in total

1.  Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.

Authors:  Jon Jacobs; Valerie Grum-Tokars; Ya Zhou; Mark Turlington; S Adrian Saldanha; Peter Chase; Aimee Eggler; Eric S Dawson; Yahira M Baez-Santos; Sakshi Tomar; Anna M Mielech; Susan C Baker; Craig W Lindsley; Peter Hodder; Andrew Mesecar; Shaun R Stauffer
Journal:  J Med Chem       Date:  2013-01-03       Impact factor: 7.446

Review 2.  Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds.

Authors:  Jiajie Zhu; Haiyan Zhang; Qinghong Lin; Jingting Lyu; Lu Lu; Hanxi Chen; Xuning Zhang; Yanjun Zhang; Keda Chen
Journal:  Drug Des Devel Ther       Date:  2022-04-08       Impact factor: 4.319

3.  Perspectives on SARS-CoV-2 Main Protease Inhibitors.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Jetze J Tepe; Faqing Huang; Guo-Wei Wei
Journal:  J Med Chem       Date:  2021-11-19       Impact factor: 8.039

4.  Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study.

Authors:  Michael Berry; Burtram C Fielding; Junaid Gamieldien
Journal:  Viruses       Date:  2015-12-15       Impact factor: 5.048

5.  Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.

Authors:  Guoying Ni; Shu Chen; Yuedong Yang; Scott F Cummins; Jian Zhan; Zhixiu Li; Bin Zhu; Kate Mounsey; Shelley Walton; Ming Q Wei; Yuejian Wang; Yaoqi Zhou; Tianfang Wang; Xiaosong Liu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 6.  Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.

Authors:  Abhik Paul; Arnab Sarkar; Sanjukta Saha; Avik Maji; Pritha Janah; Tapan Kumar Maity
Journal:  Bioorg Med Chem       Date:  2021-07-03       Impact factor: 3.641

7.  Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.

Authors:  Sivakoteswara Rao Mandadapu; Pathum M Weerawarna; Allan M Prior; Roxanne Adeline Z Uy; Sridhar Aravapalli; Kevin R Alliston; Gerald H Lushington; Yunjeong Kim; Duy H Hua; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

8.  Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding.

Authors:  Mark Turlington; Aspen Chun; Sakshi Tomar; Aimee Eggler; Valerie Grum-Tokars; Jon Jacobs; J Scott Daniels; Eric Dawson; Adrian Saldanha; Peter Chase; Yahira M Baez-Santos; Craig W Lindsley; Peter Hodder; Andrew D Mesecar; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2013-09-07       Impact factor: 2.823

Review 9.  Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics.

Authors:  Arun K Ghosh; Margherita Brindisi; Dana Shahabi; Mackenzie E Chapman; Andrew D Mesecar
Journal:  ChemMedChem       Date:  2020-05-07       Impact factor: 3.540

10.  Hemiacetal stabilization in a chymotrypsin inhibitor complex and the reactivity of the hydroxyl group of the catalytic serine residue of chymotrypsin.

Authors:  Jennifer A Cleary; William Doherty; Paul Evans; J Paul G Malthouse
Journal:  Biochim Biophys Acta       Date:  2014-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.